APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orally Disintegrating Tablet Excipient

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications.An excipient is a pharmacologically inert adhesive substance used to bind the contents of a pill or tablet. This type of tablet separates in the mouth in contact with saliva, making it easy for a person to swallow the tablet without drinking water.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications.An excipient is a pharmacologically inert adhesive substance used to bind the contents of a pill or tablet. This type of tablet separates in the mouth in contact with saliva, making it easy for a person to swallow the tablet without drinking water.

Selected research

Market Outlook & Growth Opportunities

Global Orally Disintegrating Tablet Excipient Market Outlook and Growth Opportunities 2026

Report ID 174020370420 December 2025196 pages

Choose your research edition.

Industry ResearchOrally Disintegrating Tablet Excipient Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Disintegrating Tablet Excipient Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Orally Disintegrating Tablet Excipient Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Disintegrating Tablet Excipient Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Disintegrating Tablet Excipient Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications.An excipient is a pharmacologically inert adhesive substance used to bind the contents of a pill or tablet. This type of tablet separates in the mouth in contact with saliva, making it easy for a person to swallow the tablet without drinking water.

McePharma (Vivesa holding) was the global greatest company in Orally Disintegrating Tablet Excipient industry, with the revenue market Share of 3% , followed by BASF, JRS Pharma, Roquette, ABF Ingredients, DFE Pharma, Evonik, Merck KGaA, Ashland, Meggle Pharma, Shin-Etsu, Fuji Chemical Industries, Cargill Incorporated, Daicel Corporation, Anhui Sunhere Pharmaceutical.APAC is the largest Orally Disintegrating Tablet Excipient market with about 30% market share. Americas is follower, accounting for about 27% market share.

This report provides an overview of the global Orally Disintegrating Tablet Excipient market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Orally Disintegrating Tablet Excipient and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orally Disintegrating Tablet Excipient sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Orally Disintegrating Tablet Excipient market size, projected growth trends, production technologies, key applications, and end-use industries.

Orally Disintegrating Tablet Excipient Segment by Company

BASF

JRS Pharma

Roquette

ABF Ingredients

DFE Pharma

Evonik

Merck KGaA

Ashland

Meggle Pharma

Shin-Etsu

Fuji Chemical Industries

McePharma (Vivesa holding)

Cargill Incorporated

Daicel Corporation

Anhui Sunhere Pharmaceutical

Orally Disintegrating Tablet Excipient Segment by Type

Binders

Glidents

Diluents

Disintegrants

Others

Orally Disintegrating Tablet Excipient Segment by Application

Anti-Psychotics Drug

Anti-Epileptics Drug

Others

Orally Disintegrating Tablet Excipient Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Orally Disintegrating Tablet Excipient status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Orally Disintegrating Tablet Excipient market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orally Disintegrating Tablet Excipient significant trends, drivers, influence factors in global and regions.

6. To analyze Orally Disintegrating Tablet Excipient competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Disintegrating Tablet Excipient market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Disintegrating Tablet Excipient and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Disintegrating Tablet Excipient.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Orally Disintegrating Tablet Excipient market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orally Disintegrating Tablet Excipient industry.

Chapter 3: Detailed analysis of Orally Disintegrating Tablet Excipient manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Orally Disintegrating Tablet Excipient in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Orally Disintegrating Tablet Excipient in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orally Disintegrating Tablet Excipient Industry Trends Table 2. Orally Disintegrating Tablet Excipient Industry Drivers Table 3. Orally Disintegrating Tablet Excipient Industry Opportunities and Challenges Table 4. Orally Disintegrating Tablet Excipient Industry Restraints Table 5. Global Orally Disintegrating Tablet Excipient Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orally Disintegrating Tablet Excipient Revenue Share by Company (2021-2026) Table 7. Global Orally Disintegrating Tablet Excipient Sales Volume by Company (K MT) & (2021-2026) Table 8. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Company (2021-2026) Table 9. Global Orally Disintegrating Tablet Excipient Average Price (USD/MT) of Company (2021-2026) Table 10. Global Orally Disintegrating Tablet Excipient Company Ranking, (2024-2026) & (USD Million) Table 11. Global Orally Disintegrating Tablet Excipient Key Company Manufacturing Base & Headquarters Table 12. Global Orally Disintegrating Tablet Excipient Company, Product Type & Application Table 13. Global Orally Disintegrating Tablet Excipient Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Orally Disintegrating Tablet Excipient by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Binders Table 18. Significant Companies of Glidents Table 19. Significant Companies of Diluents Table 20. Significant Companies of Disintegrants Table 21. Significant Companies of Others Table 22. Global Orally Disintegrating Tablet Excipient Sales Volume by Type 2021 VS 2025 VS 2032 (K MT) Table 23. Global Orally Disintegrating Tablet Excipient Sales Volume by Type (2021-2026) & (K MT) Table 24. Global Orally Disintegrating Tablet Excipient Sales Volume by Type (2027-2032) & (K MT) Table 25. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Type (2021-2026) Table 26. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Type (2027-2032) Table 27. Global Orally Disintegrating Tablet Excipient Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Orally Disintegrating Tablet Excipient Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Orally Disintegrating Tablet Excipient Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Orally Disintegrating Tablet Excipient Sales Value Share by Type (2021-2026) Table 31. Global Orally Disintegrating Tablet Excipient Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Anti-Psychotics Drug Table 33. Significant Companies of Anti-Epileptics Drug Table 34. Significant Companies of Others Table 35. Global Orally Disintegrating Tablet Excipient Sales Volume by Application 2021 VS 2025 VS 2032 (K MT) Table 36. Global Orally Disintegrating Tablet Excipient Sales Volume by Application (2021-2026) & (K MT) Table 37. Global Orally Disintegrating Tablet Excipient Sales Volume by Application (2027-2032) & (K MT) Table 38. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Application (2021-2026) Table 39. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Application (2027-2032) Table 40. Global Orally Disintegrating Tablet Excipient Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Orally Disintegrating Tablet Excipient Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Orally Disintegrating Tablet Excipient Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Orally Disintegrating Tablet Excipient Sales Value Share by Application (2021-2026) Table 44. Global Orally Disintegrating Tablet Excipient Sales Value Share by Application (2027-2032) Table 45. Global Orally Disintegrating Tablet Excipient Sales by Region: 2021 VS 2025 VS 2032 (K MT) Table 46. Global Orally Disintegrating Tablet Excipient Sales by Region (2021-2026) & (K MT) Table 47. Global Orally Disintegrating Tablet Excipient Sales Market Share by Region (2021-2026) Table 48. Global Orally Disintegrating Tablet Excipient Sales by Region (2027-2032) & (K MT) Table 49. Global Orally Disintegrating Tablet Excipient Sales Market Share by Region (2027-2032) Table 50. Global Orally Disintegrating Tablet Excipient Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Orally Disintegrating Tablet Excipient Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Orally Disintegrating Tablet Excipient Sales Value Share by Region (2021-2026) Table 53. Global Orally Disintegrating Tablet Excipient Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Orally Disintegrating Tablet Excipient Sales Value Share by Region (2027-2032) Table 55. Global Orally Disintegrating Tablet Excipient Market Average Price (USD/MT) by Region (2021-2026) Table 56. Global Orally Disintegrating Tablet Excipient Market Average Price (USD/MT) by Region (2027-2032) Table 57. Global Orally Disintegrating Tablet Excipient Sales by Country: 2021 VS 2025 VS 2032 (K MT) Table 58. Global Orally Disintegrating Tablet Excipient Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Orally Disintegrating Tablet Excipient Sales by Country (2021-2026) & (K MT) Table 60. Global Orally Disintegrating Tablet Excipient Sales Market Share by Country (2021-2026) Table 61. Global Orally Disintegrating Tablet Excipient Sales by Country (2027-2032) & (K MT) Table 62. Global Orally Disintegrating Tablet Excipient Sales Market Share by Country (2027-2032) Table 63. Global Orally Disintegrating Tablet Excipient Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Orally Disintegrating Tablet Excipient Sales Value Market Share by Country (2021-2026) Table 65. Global Orally Disintegrating Tablet Excipient Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Orally Disintegrating Tablet Excipient Sales Value Market Share by Country (2027-2032) Table 67. BASF Company Information Table 68. BASF Business Overview Table 69. BASF Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 70. BASF Orally Disintegrating Tablet Excipient Product Portfolio Table 71. BASF Recent Development Table 72. JRS Pharma Company Information Table 73. JRS Pharma Business Overview Table 74. JRS Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 75. JRS Pharma Orally Disintegrating Tablet Excipient Product Portfolio Table 76. JRS Pharma Recent Development Table 77. Roquette Company Information Table 78. Roquette Business Overview Table 79. Roquette Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 80. Roquette Orally Disintegrating Tablet Excipient Product Portfolio Table 81. Roquette Recent Development Table 82. ABF Ingredients Company Information Table 83. ABF Ingredients Business Overview Table 84. ABF Ingredients Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 85. ABF Ingredients Orally Disintegrating Tablet Excipient Product Portfolio Table 86. ABF Ingredients Recent Development Table 87. DFE Pharma Company Information Table 88. DFE Pharma Business Overview Table 89. DFE Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 90. DFE Pharma Orally Disintegrating Tablet Excipient Product Portfolio Table 91. DFE Pharma Recent Development Table 92. Evonik Company Information Table 93. Evonik Business Overview Table 94. Evonik Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 95. Evonik Orally Disintegrating Tablet Excipient Product Portfolio Table 96. Evonik Recent Development Table 97. Merck KGaA Company Information Table 98. Merck KGaA Business Overview Table 99. Merck KGaA Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 100. Merck KGaA Orally Disintegrating Tablet Excipient Product Portfolio Table 101. Merck KGaA Recent Development Table 102. Ashland Company Information Table 103. Ashland Business Overview Table 104. Ashland Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 105. Ashland Orally Disintegrating Tablet Excipient Product Portfolio Table 106. Ashland Recent Development Table 107. Meggle Pharma Company Information Table 108. Meggle Pharma Business Overview Table 109. Meggle Pharma Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 110. Meggle Pharma Orally Disintegrating Tablet Excipient Product Portfolio Table 111. Meggle Pharma Recent Development Table 112. Shin-Etsu Company Information Table 113. Shin-Etsu Business Overview Table 114. Shin-Etsu Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 115. Shin-Etsu Orally Disintegrating Tablet Excipient Product Portfolio Table 116. Shin-Etsu Recent Development Table 117. Fuji Chemical Industries Company Information Table 118. Fuji Chemical Industries Business Overview Table 119. Fuji Chemical Industries Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 120. Fuji Chemical Industries Orally Disintegrating Tablet Excipient Product Portfolio Table 121. Fuji Chemical Industries Recent Development Table 122. McePharma (Vivesa holding) Company Information Table 123. McePharma (Vivesa holding) Business Overview Table 124. McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 125. McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Product Portfolio Table 126. McePharma (Vivesa holding) Recent Development Table 127. Cargill Incorporated Company Information Table 128. Cargill Incorporated Business Overview Table 129. Cargill Incorporated Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 130. Cargill Incorporated Orally Disintegrating Tablet Excipient Product Portfolio Table 131. Cargill Incorporated Recent Development Table 132. Daicel Corporation Company Information Table 133. Daicel Corporation Business Overview Table 134. Daicel Corporation Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 135. Daicel Corporation Orally Disintegrating Tablet Excipient Product Portfolio Table 136. Daicel Corporation Recent Development Table 137. Anhui Sunhere Pharmaceutical Company Information Table 138. Anhui Sunhere Pharmaceutical Business Overview Table 139. Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 140. Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Product Portfolio Table 141. Anhui Sunhere Pharmaceutical Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Orally Disintegrating Tablet Excipient Distributors List Table 145. Orally Disintegrating Tablet Excipient Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Orally Disintegrating Tablet Excipient Product Image Figure 2. Global Orally Disintegrating Tablet Excipient Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 4. Global Orally Disintegrating Tablet Excipient Sales (2021-2032) & (K MT) Figure 5. Global Orally Disintegrating Tablet Excipient Sales Average Price (USD/MT) & (2021-2032) Figure 6. Global Orally Disintegrating Tablet Excipient Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Binders Image Figure 10. Glidents Image Figure 11. Diluents Image Figure 12. Disintegrants Image Figure 13. Others Image Figure 14. Global Orally Disintegrating Tablet Excipient Sales Volume by Type (2021 VS 2025 VS 2032) & (K MT) Figure 15. Global Orally Disintegrating Tablet Excipient Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Type (2021-2032) Figure 17. Global Orally Disintegrating Tablet Excipient Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Orally Disintegrating Tablet Excipient Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Orally Disintegrating Tablet Excipient Sales Value Share by Type (2021-2032) Figure 20. Anti-Psychotics Drug Image Figure 21. Anti-Epileptics Drug Image Figure 22. Others Image Figure 23. Global Orally Disintegrating Tablet Excipient Sales Volume by Application (2021 VS 2025 VS 2032) & (K MT) Figure 24. Global Orally Disintegrating Tablet Excipient Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Orally Disintegrating Tablet Excipient Sales Volume Share by Application (2021-2032) Figure 26. Global Orally Disintegrating Tablet Excipient Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Orally Disintegrating Tablet Excipient Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Orally Disintegrating Tablet Excipient Sales Value Share by Application (2021-2032) Figure 29. Global Orally Disintegrating Tablet Excipient Sales by Region: 2021 VS 2025 VS 2032 (K MT) Figure 30. Global Orally Disintegrating Tablet Excipient Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Orally Disintegrating Tablet Excipient Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Orally Disintegrating Tablet Excipient Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 34. North America Orally Disintegrating Tablet Excipient Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Orally Disintegrating Tablet Excipient Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Orally Disintegrating Tablet Excipient Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 40. South America Orally Disintegrating Tablet Excipient Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Orally Disintegrating Tablet Excipient Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Orally Disintegrating Tablet Excipient Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Orally Disintegrating Tablet Excipient Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Orally Disintegrating Tablet Excipient Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Binders
  • Glidents
  • Diluents
  • Disintegrants
  • Others
Applications
  • Anti-Psychotics Drug
  • Anti-Epileptics Drug
  • Others
Companies covered
  • BASF
  • JRS Pharma
  • Roquette
  • ABF Ingredients
  • DFE Pharma
  • Evonik
  • Merck KGaA
  • Ashland
  • Meggle Pharma
  • Shin-Etsu
  • Fuji Chemical Industries
  • McePharma (Vivesa holding)
  • Cargill Incorporated
  • Daicel Corporation
  • Anhui Sunhere Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  4. 1.2.2 Global Orally Disintegrating Tablet Excipient Sales Volume (2021-2032)
  5. 1.2.3 Global Orally Disintegrating Tablet Excipient Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Orally Disintegrating Tablet Excipient Market Dynamics
  1. 2.1 Orally Disintegrating Tablet Excipient Industry Trends
  2. 2.2 Orally Disintegrating Tablet Excipient Industry Drivers
  3. 2.3 Orally Disintegrating Tablet Excipient Industry Opportunities and Challenges
  4. 2.4 Orally Disintegrating Tablet Excipient Industry Restraints
3 Orally Disintegrating Tablet Excipient Market by Company
  1. 3.1 Global Orally Disintegrating Tablet Excipient Company Revenue Ranking in 2025
  2. 3.2 Global Orally Disintegrating Tablet Excipient Revenue by Company (2021-2026)
  3. 3.3 Global Orally Disintegrating Tablet Excipient Sales Volume by Company (2021-2026)
  4. 3.4 Global Orally Disintegrating Tablet Excipient Average Price by Company (2021-2026)
  5. 3.5 Global Orally Disintegrating Tablet Excipient Company Ranking (2024-2026)
  6. 3.6 Global Orally Disintegrating Tablet Excipient Company Manufacturing Base and Headquarters
  7. 3.7 Global Orally Disintegrating Tablet Excipient Company Product Type and Application
  8. 3.8 Global Orally Disintegrating Tablet Excipient Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Orally Disintegrating Tablet Excipient Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Orally Disintegrating Tablet Excipient Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Orally Disintegrating Tablet Excipient Market by Type
  1. 4.1 Orally Disintegrating Tablet Excipient Type Introduction
  2. 4.1.1 Binders
  3. 4.1.2 Glidents
  4. 4.1.3 Diluents
  5. 4.1.4 Disintegrants
  6. 4.1.5 Others
  7. 4.2 Global Orally Disintegrating Tablet Excipient Sales Volume by Type
  8. 4.2.1 Global Orally Disintegrating Tablet Excipient Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Orally Disintegrating Tablet Excipient Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Orally Disintegrating Tablet Excipient Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Orally Disintegrating Tablet Excipient Sales Value by Type
  12. 4.3.1 Global Orally Disintegrating Tablet Excipient Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Orally Disintegrating Tablet Excipient Sales Value by Type (2021-2032)
  14. 4.3.3 Global Orally Disintegrating Tablet Excipient Sales Value Share by Type (2021-2032)
5 Orally Disintegrating Tablet Excipient Market by Application
  1. 5.1 Orally Disintegrating Tablet Excipient Application Introduction
  2. 5.1.1 Anti-Psychotics Drug
  3. 5.1.2 Anti-Epileptics Drug
  4. 5.1.3 Others
  5. 5.2 Global Orally Disintegrating Tablet Excipient Sales Volume by Application
  6. 5.2.1 Global Orally Disintegrating Tablet Excipient Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Orally Disintegrating Tablet Excipient Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Orally Disintegrating Tablet Excipient Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Orally Disintegrating Tablet Excipient Sales Value by Application
  10. 5.3.1 Global Orally Disintegrating Tablet Excipient Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Orally Disintegrating Tablet Excipient Sales Value by Application (2021-2032)
  12. 5.3.3 Global Orally Disintegrating Tablet Excipient Sales Value Share by Application (2021-2032)
6 Orally Disintegrating Tablet Excipient Regional Sales and Value Analysis
  1. 6.1 Global Orally Disintegrating Tablet Excipient Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orally Disintegrating Tablet Excipient Sales by Region (2021-2032)
  3. 6.2.1 Global Orally Disintegrating Tablet Excipient Sales by Region: 2021-2026
  4. 6.2.2 Global Orally Disintegrating Tablet Excipient Sales by Region (2027-2032)
  5. 6.3 Global Orally Disintegrating Tablet Excipient Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Orally Disintegrating Tablet Excipient Sales Value by Region (2021-2032)
  7. 6.4.1 Global Orally Disintegrating Tablet Excipient Sales Value by Region: 2021-2026
  8. 6.4.2 Global Orally Disintegrating Tablet Excipient Sales Value by Region (2027-2032)
  9. 6.5 Global Orally Disintegrating Tablet Excipient Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  12. 6.6.2 North America Orally Disintegrating Tablet Excipient Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  15. 6.7.2 Europe Orally Disintegrating Tablet Excipient Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Orally Disintegrating Tablet Excipient Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  21. 6.9.2 South America Orally Disintegrating Tablet Excipient Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Orally Disintegrating Tablet Excipient Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Orally Disintegrating Tablet Excipient Sales Value Share by Country, 2025 VS 2032
7 Orally Disintegrating Tablet Excipient Country-level Sales and Value Analysis
  1. 7.1 Global Orally Disintegrating Tablet Excipient Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orally Disintegrating Tablet Excipient Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Orally Disintegrating Tablet Excipient Sales by Country (2021-2032)
  4. 7.3.1 Global Orally Disintegrating Tablet Excipient Sales by Country (2021-2026)
  5. 7.3.2 Global Orally Disintegrating Tablet Excipient Sales by Country (2027-2032)
  6. 7.4 Global Orally Disintegrating Tablet Excipient Sales Value by Country (2021-2032)
  7. 7.4.1 Global Orally Disintegrating Tablet Excipient Sales Value by Country (2021-2026)
  8. 7.4.2 Global Orally Disintegrating Tablet Excipient Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Orally Disintegrating Tablet Excipient Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Orally Disintegrating Tablet Excipient Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Orally Disintegrating Tablet Excipient Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BASF
  2. 8.1.1 BASF Company Information
  3. 8.1.2 BASF Business Overview
  4. 8.1.3 BASF Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 BASF Orally Disintegrating Tablet Excipient Product Portfolio
  6. 8.1.5 BASF Recent Developments
  7. 8.2 JRS Pharma
  8. 8.2.1 JRS Pharma Company Information
  9. 8.2.2 JRS Pharma Business Overview
  10. 8.2.3 JRS Pharma Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 JRS Pharma Orally Disintegrating Tablet Excipient Product Portfolio
  12. 8.2.5 JRS Pharma Recent Developments
  13. 8.3 Roquette
  14. 8.3.1 Roquette Company Information
  15. 8.3.2 Roquette Business Overview
  16. 8.3.3 Roquette Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roquette Orally Disintegrating Tablet Excipient Product Portfolio
  18. 8.3.5 Roquette Recent Developments
  19. 8.4 ABF Ingredients
  20. 8.4.1 ABF Ingredients Company Information
  21. 8.4.2 ABF Ingredients Business Overview
  22. 8.4.3 ABF Ingredients Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 ABF Ingredients Orally Disintegrating Tablet Excipient Product Portfolio
  24. 8.4.5 ABF Ingredients Recent Developments
  25. 8.5 DFE Pharma
  26. 8.5.1 DFE Pharma Company Information
  27. 8.5.2 DFE Pharma Business Overview
  28. 8.5.3 DFE Pharma Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 DFE Pharma Orally Disintegrating Tablet Excipient Product Portfolio
  30. 8.5.5 DFE Pharma Recent Developments
  31. 8.6 Evonik
  32. 8.6.1 Evonik Company Information
  33. 8.6.2 Evonik Business Overview
  34. 8.6.3 Evonik Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Evonik Orally Disintegrating Tablet Excipient Product Portfolio
  36. 8.6.5 Evonik Recent Developments
  37. 8.7 Merck KGaA
  38. 8.7.1 Merck KGaA Company Information
  39. 8.7.2 Merck KGaA Business Overview
  40. 8.7.3 Merck KGaA Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck KGaA Orally Disintegrating Tablet Excipient Product Portfolio
  42. 8.7.5 Merck KGaA Recent Developments
  43. 8.8 Ashland
  44. 8.8.1 Ashland Company Information
  45. 8.8.2 Ashland Business Overview
  46. 8.8.3 Ashland Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Ashland Orally Disintegrating Tablet Excipient Product Portfolio
  48. 8.8.5 Ashland Recent Developments
  49. 8.9 Meggle Pharma
  50. 8.9.1 Meggle Pharma Company Information
  51. 8.9.2 Meggle Pharma Business Overview
  52. 8.9.3 Meggle Pharma Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Meggle Pharma Orally Disintegrating Tablet Excipient Product Portfolio
  54. 8.9.5 Meggle Pharma Recent Developments
  55. 8.10 Shin-Etsu
  56. 8.10.1 Shin-Etsu Company Information
  57. 8.10.2 Shin-Etsu Business Overview
  58. 8.10.3 Shin-Etsu Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shin-Etsu Orally Disintegrating Tablet Excipient Product Portfolio
  60. 8.10.5 Shin-Etsu Recent Developments
  61. 8.11 Fuji Chemical Industries
  62. 8.11.1 Fuji Chemical Industries Company Information
  63. 8.11.2 Fuji Chemical Industries Business Overview
  64. 8.11.3 Fuji Chemical Industries Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Fuji Chemical Industries Orally Disintegrating Tablet Excipient Product Portfolio
  66. 8.11.5 Fuji Chemical Industries Recent Developments
  67. 8.12 McePharma (Vivesa holding)
  68. 8.12.1 McePharma (Vivesa holding) Company Information
  69. 8.12.2 McePharma (Vivesa holding) Business Overview
  70. 8.12.3 McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 McePharma (Vivesa holding) Orally Disintegrating Tablet Excipient Product Portfolio
  72. 8.12.5 McePharma (Vivesa holding) Recent Developments
  73. 8.13 Cargill Incorporated
  74. 8.13.1 Cargill Incorporated Company Information
  75. 8.13.2 Cargill Incorporated Business Overview
  76. 8.13.3 Cargill Incorporated Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Cargill Incorporated Orally Disintegrating Tablet Excipient Product Portfolio
  78. 8.13.5 Cargill Incorporated Recent Developments
  79. 8.14 Daicel Corporation
  80. 8.14.1 Daicel Corporation Company Information
  81. 8.14.2 Daicel Corporation Business Overview
  82. 8.14.3 Daicel Corporation Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Daicel Corporation Orally Disintegrating Tablet Excipient Product Portfolio
  84. 8.14.5 Daicel Corporation Recent Developments
  85. 8.15 Anhui Sunhere Pharmaceutical
  86. 8.15.1 Anhui Sunhere Pharmaceutical Company Information
  87. 8.15.2 Anhui Sunhere Pharmaceutical Business Overview
  88. 8.15.3 Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Anhui Sunhere Pharmaceutical Orally Disintegrating Tablet Excipient Product Portfolio
  90. 8.15.5 Anhui Sunhere Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Orally Disintegrating Tablet Excipient Value Chain Analysis
  2. 9.1.1 Orally Disintegrating Tablet Excipient Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Orally Disintegrating Tablet Excipient Sales Mode & Process
  6. 9.2 Orally Disintegrating Tablet Excipient Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Orally Disintegrating Tablet Excipient Distributors
  9. 9.2.3 Orally Disintegrating Tablet Excipient Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst